Silence Therapeutics plc
SLN
$13.55
-$0.14-1.02%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 55.15% | 47.57% | -195.68% | 41.04% | -38.47% |
| Total Depreciation and Amortization | -27.03% | -23.19% | -19.29% | 3.31% | -1.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -90.90% | -65.96% | 91.99% | -93.32% | 204.14% |
| Change in Net Operating Assets | 383.76% | -125.30% | 84.07% | 412.19% | -141.18% |
| Cash from Operations | 106.97% | -26.76% | 37.09% | 57.47% | -302.74% |
| Capital Expenditure | -- | -- | 100.00% | 95.31% | 43.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 4,389.30% | 122.53% | -180.59% | 234.71% | -3,704.76% |
| Cash from Investing | 4,257.49% | 122.53% | -180.66% | 234.48% | -3,532.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 100.00% | -- | -- | -100.00% | -99.92% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 100.00% | -- | 100.00% | -100.00% | -99.92% |
| Foreign Exchange rate Adjustments | -131.82% | -107.33% | 18.87% | -139.55% | 1,514.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 386.85% | 90.04% | -284.32% | 172.59% | -441.70% |